Gradalis

About:

Gradalis is engaged in manufacturing immunotherapy for the treatment of cancer.

Website: http://www.gradalisinc.com

Twitter/X: gradalis_inc

Top Investors: Cancer Prevention and Research Institute of Texas

Description:

Gradalis is a late stage biotechnology company focused on the development and commercialization of novel personalized therapeutics to treat cancer. We are developing Vigil, our proprietary immunotherapy platform in multiple advanced cancer indications with the lead program for the treatment of patients with Ewing's sarcoma.

Total Funding Amount:

$77.8M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Carrollton, Texas, United States

Founded Date:

2003-01-01

Contact Email:

info(AT)gradalisinc.com

Founders:

David Shanahan, John Nemunaitis

Number of Employees:

11-50

Last Funding Date:

2023-11-16

IPO Status:

Private

Industries:

© 2025 bioDAO.ai